Skip to main content

Gefapixant A P2X3 Receptor Antagonist For The Treatment Of Refractory Or Unexplained Chronic Cough In A Phase 2b Randomised Controlled Trial (2020)
Journal Article
Smith, J. A., Kitt, M. M., Morice, A. H., Birring, S. S., McGarvey, L. P., Sher, M. R., …Ford, A. P. (in press). Gefapixant A P2X3 Receptor Antagonist For The Treatment Of Refractory Or Unexplained Chronic Cough In A Phase 2b Randomised Controlled Trial. The lancet. Respiratory medicine, https://doi.org/10.1016/S2213-2600%2819%2930471-0

Background: Gefapixant is a P2X3 receptor antagonist in development for treatment of refractory (RCC) and unexplained chronic cough (UCC). Methods: We conducted a 12-week, Phase 2b, randomized, double-blind, placebo-controlled study in patients w... Read More about Gefapixant A P2X3 Receptor Antagonist For The Treatment Of Refractory Or Unexplained Chronic Cough In A Phase 2b Randomised Controlled Trial.

Randomised, double-blind, multi-centre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B Feasibility) (2020)
Journal Article
Higginson, I., Wilcock, A., Johnson, M., Bajwah, S., Currow, D., Lovell, N., …Brown, S. (2020). Randomised, double-blind, multi-centre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B Feasibility). Thorax, https://doi.org/10.1136/thoraxjnl-2019-213879

New treatments are required for severe breathlessness in advanced disease. We conducted a randomised feasibility trial of mirtazapine over 28 days in adults with a modified medical research council breathlessness scale score ≥3. Sixty-four patients w... Read More about Randomised, double-blind, multi-centre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B Feasibility).


;